TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17074322
Drug: Modified ovarian
Normalized name: Autologous, DNP-Modified Ovarian Cancer Vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified ovarian age-based stimulation with microdose GnRH agonist (GnRH-a) and 450-600 IU of gonadotropin daily.
Study: 9233079
Drug: Training workshop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training workshop for selected members to spread knowledge and skills of oral rehydration therapy.
Study: 29851791
Drug: Anti-TB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TB therapy with isoniazid, rifampicin, ethambutol, and pyrazinamide for 6 months
Study: 26047975
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TA-8995
Study: 23437399
Drug: Laboratory and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laboratory and Clinical Monitoring (LCM, 12-weekly CD4s)
Study: 12728487
Drug: Fentanyl 0.3
Normalized name: fentanyl 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.3 ml (15 micrograms) added to 0.5% hyperbaric bupivacaine 2.0 ml
Study: 12728487
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline 0.3 ml added to 0.5% hyperbaric bupivacaine 2.0 ml
Study: 11483142
Drug: Neurocognitive enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurocognitive enhancement therapy (NET) plus work therapy (WT)
Study: 11483142
Drug: Work therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work therapy (WT) alone
Study: 26056838
Drug: PVB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVB with catheter at level Th 4, 10 ml each of 1:2 mixture of bupivacaine 0.5% and lidocaine 2% with adrenaline injected at three different levels
Study: 23165913
Drug: Lactitol treatment
Normalized name: Lactitol
DrugBank: Lactitol (DB12942)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactitol treatment
Study: 21639927
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus cooling (target rectal temperature of 33-34°C for 72 hrs, started within 3 h of birth)
Study: 16546486
Drug: PSE margarine
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSE margarine (3 g)
Study: 16546486
Drug: Placebo margarine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo margarine (0 g)
Study: 12775317
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using topical methyl aminolevulinate (Metvix)
Study: 6152058
Drug: RS 86,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS 86, 0.5-4 mg orally
Study: 6152058
Drug: RS 86,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS 86, 4 mg orally
Study: 30073931
Drug: Silymarin 420
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 420 mg/day for one week after each doxorubicin dose
Study: 30089301
Drug: Vancomycin (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (7 days, 1,500 mg/day)
Study: 27456342
Drug: 1-week free
Normalized name: Free Cysteine
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-week free nicotine replacement therapy (NRT) sample and medication counselling
Study: 23477217
Drug: Systemic enzyme
Normalized name: alpha-D-galactosidase enzyme Chewable Tablet [Beano]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic enzyme therapy in combination with antibiotics
Study: 9360863
Drug: Ascending runs
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascending runs in sequential presentation
Study: 9360863
Drug: Descending runs
Normalized name: Defend II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Descending runs in sequential presentation
Study: 26365936
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard-dose clopidogrel)
Study: 7570132
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine sulphate in 20 ml saline (Group A)
Study: 7570132
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.25% bupivacaine (Group B)
Study: 7570132
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg morphine sulphate in 20 ml of 0.25% bupivacaine (Group C)
Study: 7570132
Drug: No intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intra-articular injection (Group D)
Study: 7400107
Drug: Sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release methylphenidate (20 mg once daily)
Study: 7400107
Drug: Standard methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard methylphenidate (10 mg twice daily)
Study: 29691998
Drug: TEAR treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEAR treatment arms
Study: 29691998
Drug: RACAT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RACAT treatment arms
Study: 29691998
Drug: RACAT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RACAT treatment response
Study: 28177481
Drug: Illicit drugs
Normalized name: Illicium difengpi bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Illicit drugs for pain relief
Study: 19568178
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg LDECA plus 30 mg lansoprazole
Study: 19568178
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg LDECA
Study: 9894371
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose (LD) budesonide (400 micrograms twice daily for 6 weeks, then 400 micrograms nocte for 12 weeks)
Study: 9894371
Drug: Static dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static dose (SD) budesonide (400 micrograms nocte for 18 weeks)
Study: 9894371
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose (LD) budesonide (400 micrograms twice daily for 6 weeks)
Study: 8115156
Drug: ProCell (DexSol
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProCell (DexSol with hEGF and insulin)
Study: 21900193
Drug: Weekly bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly bortezomib induction followed by bortezomib-based maintenance
Study: 15341437
Drug: Steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid therapy (specific type and dosage not detailed)
Study: 9692272
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/24 h for the first 6 months)
Study: 31012599
Drug: Nasal saline
Normalized name: Nasal Saline
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal saline irrigation (NSI) daily for 12 weeks
Study: 23549225
Drug: Duloxetine (30-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30-90 mg for 12 weeks)
Study: 21720661
Drug: Dapsone gel
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone gel 5% + tazarotene cream 0.1%
Study: 12734506
Drug: Tazarotene cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene cream 0.1%
Study: 16488295
Drug: Low-dose UVA1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UVA1 (20 J/cm2)
Study: 16488295
Drug: Medium-dose UVA1
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose UVA1 (50 J/cm2)
Study: 8462386
Drug: Captopril (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (initial dose: 12.5 mg daily, increased according to tolerance)
Study: 2939220
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 mg twice daily for 15 days, then 40 mg twice daily for 75 days)
Study: 2939220
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg twice daily for 90 days)
Study: 15198156
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia (75 mg bupivacaine heavy + 50 microg fentanyl)
Study: 15198156
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia (15 mg bupivacaine heavy + 50 microg fentanyl)
Study: 15198156
Drug: Saddle blockade
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saddle blockade (10 mg bupivacaine heavy + 50 microg fentanyl)
Study: 6347154
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no adjuvant immunotherapy)
Study: 27381275
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg/d
Study: 19607731
Drug: MSP3 malaria
Normalized name: PLASMODIUM MALARIAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP3 malaria vaccine (15 microg)
Study: 19607731
Drug: MSP3 malaria
Normalized name: PLASMODIUM MALARIAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP3 malaria vaccine (30 microg)
Study: 7852065
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine sulfate (morphine)
Study: 356764
Drug: Indomethacin suppositories
Normalized name: Indomethacin Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppositories
Study: 23645695
Drug: L-arginine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (100 mg/kg tid)
Study: 18347491
Drug: Antibiotics (cephalexin)
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (cephalexin)
Study: 3544968
Drug: TECA 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: TECA 120 mg/day
Study: 31994196
Drug: Phentolamine mesylate
Normalized name: Phentolamine Mesylate
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentolamine mesylate (1.7-mL OraVerse, 0.4-mg)
Study: 29651711
Drug: Baclofen 45-60
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen 45-60 mg/day for 3 months (n=37)
Study: 29651711
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU, n=70)
Study: 19902491
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents with IVUS guidance
Study: 17259789
Drug: T4-Ibsa oral
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4-Ibsa oral solution
Study: 1343144
Drug: CMF and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF and TMF chemotherapy
Study: 4068237
Drug: N-CWS immunotherapy
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-CWS immunotherapy
Study: 24882841
Drug: Control kinesiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control kinesiotherapy (using common daily-life objects)
Study: 19525335
Drug: Nabilone 1-3
Normalized name: nabilone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone 1-3 mg
Study: 18718641
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg/d) for 3 months
Study: 18718641
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg/d) for 1-4 months
Study: 21093145
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg/d)
Study: 15823654
Drug: Hand rubbing
Normalized name: ALCOHOL 0.8 TOPICAL SPRAY [Hand Rub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand rubbing with an alcoholic solution
Study: 85812
Drug: Intravenous aminoacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminoacid infusion
Study: 814825
Drug: Intravenous hyperalimentation
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hyperalimentation
Study: 25530275
Drug: Propofol combined
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol combined with 40% nitrous oxide inhalation (group N+P)
Study: 8796365
Drug: Amiodarone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone treatment for 6 months
Study: 30721652
Drug: Premature Infant
Normalized name: Premature infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premature Infant Oral Motor Intervention (PIOMI) once daily for 7 consecutive days
Study: 26650971
Drug: RBP-6000 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBP-6000 (300 mg)
Study: 26650971
Drug: Hydromorphone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (6 mg, 18 mg)
Study: 20722559
Drug: Considering eGFR
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Considering eGFR level less than 60 mL/min/1.73 m² as high risk for CIN
Study: 20722559
Drug: Considering eGFR
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Considering eGFR level less than 30 mL/min/1.73 m² as high risk for CIN
Study: 10073841
Drug: Subcutaneous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous vitamin K1
Study: 7721614
Drug: Diethylstilbestrol 1
Normalized name: diethylstilbestrol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol 1 mg three times per day by mouth
Study: 30678676
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of access to the Big White Wall (BWW) (n=57)
Study: 29432076
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy using paclitaxel and carboplatin (3 cycles, once every 3 weeks) followed by radical hysterectomy
Study: 29432076
Drug: Concomitant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemoradiation with standard cisplatin-based treatment (once every week for 5 weeks)
Study: 29432076
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus surgery
Study: 26694501
Drug: Concurrent Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Training (CT) - 4 sets of 30-s maximal effort, separated by 4 m 30-s rest intervals
Study: 23654003
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg administered 1 hour and 24 hours after phacoemulsification (Group I)
Study: 23654003
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg (Group I)
Study: 20591614
Drug: Spiritually Integrated
Normalized name: Spiritus vini
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spiritually Integrated Treatment (SIT)
Study: 17956647
Drug: EPA+DHA supplementation
Normalized name: eicosapentaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA supplementation (1.5 g/d)
Study: 8751166
Drug: Oxygen saturation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen saturation (Sao2) before medication
Study: 8751166
Drug: Oxygen saturation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen saturation (Sao2) after medication
Study: 31791396
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy for insomnia (CBTi) - six sessions
Study: 20971535
Drug: CCD (preOp(®),
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCD (preOp(®), Nutricia, UK, 50 g carbohydrate)
Study: 20971535
Drug: CCD/L (preOp(®),
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCD/L (preOp(®), 36 g carbohydrate + 7 g lipid)
Study: 20971535
Drug: CCD/G
Normalized name: Calcium Carbonate/Cholecalciferol/Glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCD/G
Study: 20971535
Drug: CCD/L
Normalized name: Calcium Carbonate/Cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCD/L
Study: 17827461
Drug: Conventional cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cytotoxic drugs or increased radiation dose
Study: 9676350
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily administration of sustained release theophylline
Study: 7986180
Drug: Adjunctive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive oral cabergoline
Study: 2733574
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (320 mg ferrous sulfate)
Study: 31575825
Drug: Caffeine 4
Normalized name: caffeine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 4 mg·kg‐1
Study: 31575825
Drug: Caffeine 2
Normalized name: caffeine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 2 mg·kg‐1
Study: 26673692
Drug: Ganglioside consumption
Normalized name: IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganglioside consumption (43 mg/d) in patients with IBD
Study: 19565735
Drug: Combined moxibustion
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined moxibustion and medicine group (n = 22)
Study: 19565735
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine group (n = 29)
Study: 19565735
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (n = 24)
Study: 16505439
Drug: PEG‐IFNalpha‐2a (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFNalpha‐2a (all doses)
Study: 14718821
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise program (therapy group) with physical therapy designed to strengthen calf musculature.
Study: 2663318
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg acetaminophen
Study: 17425493
Drug: Thrombolytic agents
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic agents
Study: 2892989
Drug: (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) plus calcium (1 g/day)
Study: 29702684
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen inhalation (Control)
Study: 23997689
Drug: Once weekly,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly, supervised hospital-based maintenance exercise plus home exercise for 12 months
Study: 21941220
Drug: Ketamine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (intravenous loading dose 0.5 mg/kg followed by 9 μg/kg per minute for 20 mins)
Study: 16470607
Drug: Prophylactic lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prophylactic lamivudine (100 mg daily before and until at least 8 weeks after chemotherapy)
Study: 31221222
Drug: Gabapentin as
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin as add-on to morphine
Study: 17768058
Drug: 7.2g alpha-ketoglutaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2g alpha-ketoglutaric acid and 720 mg 5-hydroxymethylfurfural/day (SANOPAL) from days 1 to 10
Study: 15229713
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of vitamins and minerals
Study: 12109935
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion (bupropion SR) 150mg twice daily
Study: 12109935
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion (bupropion SR) 300mg/day
Study: 12109935
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion (bupropion SR)
Study: 9817266
Drug: CA10 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA10 with moderate/high dose-volume cardiac RT
Study: 8176012
Drug: All tested
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All tested formulations
Study: 12950862
Drug: Inhaled isoflurane
Normalized name: isoflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled isoflurane
Study: 26646404
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam and/or propofol
Study: 20565044
Drug: Saint John's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saint John's Wort Extract (antidepressant treatment)
Study: 15752403
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of thermal indicator into the right ventricle
Study: 11560559
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravesical MMC plus local hyperthermia (Group 1)
Study: 9623316
Drug: Cisapride, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 3 x 5 mg in a suspension one day before surgery and 30 mg 3 and 8 hours after surgery, followed by 2 x 30 mg in suppositories until oral ingestion is possible
Study: 7910488
Drug: Antacid with
Normalized name: Antacid with Simethicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid with all agents tested
Study: 24360107
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml normal saline infusion (placebo)
Study: 24360107
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg parecoxib infusion
Study: 18422481
Drug: Other antimuscarinic
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antimuscarinic agents
Study: 10511061
Drug: DX-9065a (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: DX-9065a (0.625 to 30 mg, intravenously administered)